PURPOSE: We have conducted an initial evaluation on the potential of combining noncontrast magnetic resonance imaging (MRI) and ultrasonography (US) to screen for pancreatic cancer. MATERIALS AND METHODS: An independent ethics committee approved this study. A total of 2511 patients who underwent US were enrolled. Among them, noncontrast MRI was performed in patients in whom the entire pancreas was difficult to depict or in those with US-suspected pancreatic lesions. In total, using 1.5-T MRI, T1- and T2-weighted imaging, magnetic resonance cholangiopancreatography, and diffusion-weighted imaging, we acquired a variety of images. The efficacy of US and MRI in screening for pancreatic lesions, including pancreatic cancer, was evaluated. RESULTS: Of 2511 patients, 184 underwent MRI, and the pancreas was demonstrated in all of them. Among the 2511, five pancreatic cancers were detected by MRI combined with US (detection rate 0.20%). Of the five pancreatic cancers, three were detected by US (detection rate 0.12%) and two by MRI. Four of the five pancreatic cancers were resectable. CONCLUSION: By combining noncontrast MRI with US, pancreatic cancer can be detected with high accuracy. Other pancreatic lesions that require follow-up, including intraductal papillary mucinous neoplasms, can also be detected. Thus, pancreatic cancer screening with a combination of US and MRI is suggested.
PURPOSE: We have conducted an initial evaluation on the potential of combining noncontrast magnetic resonance imaging (MRI) and ultrasonography (US) to screen for pancreatic cancer. MATERIALS AND METHODS: An independent ethics committee approved this study. A total of 2511 patients who underwent US were enrolled. Among them, noncontrast MRI was performed in patients in whom the entire pancreas was difficult to depict or in those with US-suspected pancreatic lesions. In total, using 1.5-T MRI, T1- and T2-weighted imaging, magnetic resonance cholangiopancreatography, and diffusion-weighted imaging, we acquired a variety of images. The efficacy of US and MRI in screening for pancreatic lesions, including pancreatic cancer, was evaluated. RESULTS: Of 2511 patients, 184 underwent MRI, and the pancreas was demonstrated in all of them. Among the 2511, five pancreatic cancers were detected by MRI combined with US (detection rate 0.20%). Of the five pancreatic cancers, three were detected by US (detection rate 0.12%) and two by MRI. Four of the five pancreatic cancers were resectable. CONCLUSION: By combining noncontrast MRI with US, pancreatic cancer can be detected with high accuracy. Other pancreatic lesions that require follow-up, including intraductal papillary mucinous neoplasms, can also be detected. Thus, pancreatic cancer screening with a combination of US and MRI is suggested.
Authors: Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa Journal: Virchows Arch Date: 2005-08-09 Impact factor: 4.064
Authors: R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus Journal: Am J Surg Pathol Date: 2001-05 Impact factor: 6.394
Authors: Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa Journal: Am J Surg Pathol Date: 2004-08 Impact factor: 6.394
Authors: J Yahalom; J A Petrek; P W Biddinger; S Kessler; D D Dershaw; B McCormick; M P Osborne; D A Kinne; P P Rosen Journal: J Clin Oncol Date: 1992-11 Impact factor: 44.544
Authors: Taylor A Sohn; Charles J Yeo; John L Cameron; Ralph H Hruban; Noriyoshi Fukushima; Kurtis A Campbell; Keith D Lillemoe Journal: Ann Surg Date: 2004-06 Impact factor: 12.969
Authors: Navid Farr; Yak-Nam Wang; Samantha D'Andrea; Kayla M Gravelle; Joo Ha Hwang; Donghoon Lee Journal: Cancer Med Date: 2017-04-07 Impact factor: 4.452